Oncology
Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non–muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy
To report long-term follow-up results of a phase II trial of salvage intravesical nanoparticle albumin-bound (nab)-paclitaxel for patients with recurrent non–muscle-invasive bladder cancer after previous intravesical bacillus Calmette-Guérin (BCG) therapy.
